Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 11 clients • 11 examiners • 11 art units • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
This profile covers Biotechnology & Pharmaceuticals and includes 576 career applications. The resolved allowance rate is 77.09%, and the average is 3.87 office actions per allowance. The record shows a moderate application base, an allowance outcome for a majority of resolved matters, and repeated examination activity before allowance.
The profile contains 12 pending office actions. Practitioners can use the historical figures to frame prosecution planning, while recognizing that the reported allowance outcome does not resolve the current matters. The action average indicates that responses may require sustained engagement with the examiner, making claim strategy and timely issue resolution important for the active biotechnology and pharmaceutical docket.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (9%) |
| §101 + other | 1 (9%) |
| §103 only | 3 (27%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROOME, SHARRIEF I | 1 | 81.5% | +4.5% |
| GRAHAM, CHANTEL LORAN | 1 | 71.8% | +11.5% |
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
| MISIASZEK, AMBER ALTSCHUL | 1 | 46.8% | +24.0% |
| CLEMMONS, STEVE M | 1 | 69.7% | +20.9% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| MERTZ, PREMA MARIA | 1 | 71.8% | +34.6% |
| RIEGLER, PATRICK F | 1 | 55.3% | +30.9% |
| SAEED, ALI S | 1 | 31.6% | +33.8% |
| MORNHINWEG, JEFFREY P | 1 | 36.7% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411752 | Engine, System, and Method of Providing Automated Risk Mitigation | RIEGLER, PATRICK F | 49d overdue |
| 16625877 | KIT FOR EVALUATING GENE MUTATION RELATED TO MYELOPROLIFERATIVE TUMOR | SALMON, KATHERINE D | 14d |
| 18711261 | METHODS FOR INTRATUMORAL DELIVERY OF CRISPR/CAS SYSTEMS | ALLEY, GENEVIEVE S | 69d |
| 18997270 | LIGHT-CANCELLING ARTICLE AND PROJECTION APPARATUS | BROOME, SHARRIEF I | — |
| 18919303 | EVALUATING TOPIC TREATMENT IN ELECTRONIC COMMUNICATIONS | MISIASZEK, AMBER ALTSCHUL | — |
| 18368599 | COMPOSITIONS COMPRISING AND METHODS OF USING 1,3-PROPANEDIOL, TO IMPROVE SWEETNESS AND/OR REDUCE BITTERNESS OF SWEETENERS | MORNHINWEG, JEFFREY P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411752 | Engine, System, and Method of Providing Automated Risk Mitigation | RIEGLER, PATRICK F | 49d overdue |
| 18512349 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | SAEED, ALI S | 31d overdue |
| 18711261 | METHODS FOR INTRATUMORAL DELIVERY OF CRISPR/CAS SYSTEMS | ALLEY, GENEVIEVE S | 69d |
| 18948419 | MICROWAVE-ASSISTED CATALYTIC PYROLYSIS PROCESS AND REACTOR FOR SELECTIVELY CONVERTING ADDITIVE-CONTAINING PLASTIC TO ALKENES AND ALKANES | GRAHAM, CHANTEL LORAN | — |
| 18865479 | PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF ALOPECIA | DAVIS, RUTH A | — |
| 18919303 | EVALUATING TOPIC TREATMENT IN ELECTRONIC COMMUNICATIONS | MISIASZEK, AMBER ALTSCHUL | — |
| 18785017 | SKATEBOARD TRUCK ASSEMBLY | CLEMMONS, STEVE M | — |
| 18597286 | METHODS OF TREATING ATOPIC DERMATITIS | MERTZ, PREMA MARIA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Holotronica Limited | 1 |
| University of Delaware | 1 |
| Bioithas S.L. | 1 |
| Highspot | 1 |
| Djll Holdings, LLC | 1 |
| Christiana Care Health System | 1 |
| Receptos LLC | 1 |
| Josh Kelso | 1 |
| Productos Farmaceuticos, S.A. DE C.V. | 1 |
| Primient Covation LLC | 1 |
| Yamaguchi University | 1 |
| Art Unit | Apps |
|---|---|
| 2872 | 1 |
| 1771 | 1 |
| 1699 | 1 |
| 3682 | 1 |
| 3613 | 1 |
| 1617 | 1 |
| 1646 | 1 |
| 2171 | 1 |
| 1616 | 1 |
| 1793 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18997270 | LIGHT-CANCELLING ARTICLE AND PROJECTION APPARATUS | Holotronica Limited | BROOME, SHARRIEF I | 2872 | §102§103 | Non-Final OA | — | Pending | Jan 21, 2025 |
| 18948419 | MICROWAVE-ASSISTED CATALYTIC PYROLYSIS PROCESS AND REACTOR FOR SELECTIVELY CONVERTING ADDITIVE-CONTAINING PLASTIC TO ALKENES AND ALKANES | UNIVERSITY OF DELAWARE | GRAHAM, CHANTEL LORAN | 1771 | §103 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18865479 | PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF ALOPECIA | Bioithas S.L. | DAVIS, RUTH A | 1699 | §102§103§112DP | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18919303 | EVALUATING TOPIC TREATMENT IN ELECTRONIC COMMUNICATIONS | Highspot, Inc. | MISIASZEK, AMBER ALTSCHUL | 3682 | §101 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18785017 | SKATEBOARD TRUCK ASSEMBLY | Djll Holdings, LLC | CLEMMONS, STEVE M | 3613 | §103 | Final Rejection | — | Pending | Jul 26, 2024 |
| 18711261 | METHODS FOR INTRATUMORAL DELIVERY OF CRISPR/CAS SYSTEMS | Christiana Care Gene Editing Institute, Inc. | ALLEY, GENEVIEVE S | 1617 | §102§103 | Non-Final OA | 69d | Pending | May 17, 2024 |
| 18597286 | METHODS OF TREATING ATOPIC DERMATITIS | Receptos LLC | MERTZ, PREMA MARIA | 1646 | DP | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18411752 | Engine, System, and Method of Providing Automated Risk Mitigation | Josh Kelso | RIEGLER, PATRICK F | 2171 | §102§103 | Final Rejection | 49d overdue | Pending | Jan 12, 2024 |
| 18512349 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | Productos Farmaceuticos, S.A. De C.V. | SAEED, ALI S | 1616 | §103 | Non-Final OA | 31d overdue | Pending | Nov 17, 2023 |
| 18368599 | COMPOSITIONS COMPRISING AND METHODS OF USING 1,3-PROPANEDIOL, TO IMPROVE SWEETNESS AND/OR REDUCE BITTERNESS OF SWEETENERS | Primient Covation LLC | MORNHINWEG, JEFFREY P | 1793 | §102§103 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 16625877 | KIT FOR EVALUATING GENE MUTATION RELATED TO MYELOPROLIFERATIVE TUMOR | Yamaguchi University | SALMON, KATHERINE D | 1682 | §101§112 | Non-Final OA | 14d | Pending | Dec 23, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial77.1% of resolved applications prosecuted by Mccarter & English, LLP Wilmington were allowed, across 576 applications in USPTO records.
3.87 office actions per allowed application on average.
11 pending office actions as of October 2026, for 11 clients, before 11 examiners in 11 art units.
